Diffuse pulmonary lymphangiomatosis treated with bevacizumab

Area of Science:

• Pulmonology
• Oncology
• Vascular Biology

Background:

• Diffuse pulmonary lymphangiomatosis (DPL) is a rare condition causing respiratory issues due to lymphatic vessel overgrowth.
• Vascular endothelial growth factor (VEGF) plays a key role in lymphatic vessel development.
• Bevacizumab, an anti-VEGF antibody, is used for conditions with excessive vessel proliferation.

Observation:

• A 51-year-old male patient with DPL received bevacizumab at 1 mg/kg every three weeks for six months.
• Computed tomography (CT) scans revealed reduced lung infiltrates post-treatment.
• The patient reported subjective improvement in respiratory symptoms.

Findings:

• Pulmonary function tests demonstrated a 17.5% increase in forced expiratory volume in one second (FEV1).
• Significant improvements were noted in forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO).
• No major adverse effects related to bevacizumab were observed during the treatment period.

Implications:

• This case suggests bevacizumab may be a viable therapeutic option for DPL.
• The study highlights the potential of anti-VEGF therapy in managing DPL and improving lung function.
• Further research is warranted to confirm these findings in a larger patient cohort.